Evidence map›Paper›PMID 42718652›Full record

ArticleFrontiers in cellular and infection microbiology2026

Risk factors, resistance profiles, and clinical outcomes of

Shulei Zhang, Jingwen Wang, Shuo Zhang, Shuping Lu, Miaosu Chang, Wei Xu, Qingmei Zhang, Mei Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shulei ZhangDepartment of Clinical Laboratory, The Fourth Affiliated Hospital of Anhui Medical University, ChaoHu, Anhui, China.
Jingwen WangDepartment of Clinical Laboratory, The Fourth Affiliated Hospital of Anhui Medical University, ChaoHu, Anhui, China.
Shuo ZhangDepartment of Clinical Laboratory, The Fourth Affiliated Hospital of Anhui Medical University, ChaoHu, Anhui, China.
Shuping LuDepartment of Clinical Laboratory, The Fourth Affiliated Hospital of Anhui Medical University, ChaoHu, Anhui, China.
Miaosu ChangDepartment of Clinical Laboratory, The Fourth Affiliated Hospital of Anhui Medical University, ChaoHu, Anhui, China.
Wei XuDepartment of Blood Transfusion, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Qingmei ZhangDepartment of Anesthesiology, The Fourth Affiliated Hospital of Anhui Medical University, ChaoHu, Anhui, China.
Mei ZhuDepartment of Clinical Laboratory, The Fourth Affiliated Hospital of Anhui Medical University, ChaoHu, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cancer patients are highly susceptible to Methods: We retrospectively analyzed 300 adult cancer patients treated between October 2023 and November 2024, including 153 with KP infection and 147 uninfected controls. Data on demographics, comorbidities, invasive procedures, laboratory findings, antimicrobial resistance, treatment patterns, and outcomes were collected. Independent risk factors were identified using multivariable logistic regression, and a predictive nomogram was developed and validated. Results: The respiratory tract was the most common infection site (60.8%), followed by urinary tract (14.4%) and bloodstream (10.4%). Urinary isolates exhibited the highest rates of multidrug-resistant KP (MDR-KP, 69.6%) and extended-spectrum β-lactamase-producing KP (ESBL-KP, 60.9%). Multivariate analysis identified hypoproteinemia (odds ratio [OR] = 2.233, 95% confidence interval [CI] 1.222-4.077, Conclusion: Statistical models indicate that KP infection in cancer patients is likely linked to host immunity, invasive interventions, and treatment exposures; the nomogram can assist in early risk stratification and facilitate tailored stewardship.

Indexed as

Klebsiella InfectionsKlebsiella pneumoniaeNeoplasmsAdultAgedAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedNomogramsRetrospective StudiesRisk FactorsTreatment OutcomeAnti-Bacterial Agentscancer patientsKlebsiella pneumoniaemultidrug resistanceprediction modelrisk factors

Identifiers

PMID42718652
PMCPMC13553344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.